ANGLE signs commercial agreement with AstraZeneca
April 26, 2024Business Services Angle, AstraZeneca, Pharmacy, commercial agreement
ANGLE has announced that it has signed a supplier agreement with AstraZeneca for the development and validation of a methodology …
Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement
April 25, 2024Research and Development Oncology, Ono Pharmaceutical, Prism BioLab, research and licensing agreement
Prism BioLab has announced that it has entered into a target-exclusive research and licensing agreement with Ono Pharmaceutical. Under the …
Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment
April 25, 2024Medical Communications Ascendis Pharma, Internal Medicine, MHRA, hypoparathyroidism
Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Yorvipath …
Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals
April 24, 2024Manufacturing and Production Eli Lilly, Nexus Pharmaceuticals, Pharmacy, acquisition, facility
Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement for Eli Lilly to acquire …
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
April 24, 2024Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
April 23, 2024Research and Development Cardiology, Sanofi, clinical trial, thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib 400mg twice daily oral treatment …
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
April 23, 2024Medical Communications Anktiva, FDA, ImmunityBio, Oncology, bladder cancer
ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus …
EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment
April 22, 2024Medical Communications Emblaveo, European Commission, Immunology, Pfizer
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) for the treatment of adult …
Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder
April 22, 2024Research and Development Kaerus Bioscience, Neurolentech, Neurology, neurodevelopmental disorders, neurology
Neurolentech has announced that it has entered into a technology access partnership with Kaerus Bioscience, with the aim of driving …
Ardena announces €20m expansion following first GMP approval
April 19, 2024Manufacturing and Production Ardena, Pharmacy, facility, manufacturing
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new …
Roche’s Alecensa approved by FDA as lung cancer treatment
April 19, 2024Medical Communications FDA, Oncology, Roche, lung cancer
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …
GSK shares results from phase 3 trial for gonorrhoea treatment
April 18, 2024Research and Development GSK, Reproductive health, clinical trial, gonorrhoea, sexual health
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential first-in-class oral antibiotic for the …
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
April 18, 2024Research and Development Ear Nose & throat, Eli Lilly, clinical trial, sleep apnoea, tirzepatide
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated that tizepatide injection (10mg or …
Medincell and AbbVie enter agreement for development of next-generation injectables
April 17, 2024Research and Development AbbVie, Immunology, Medincell, collaboration
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and commercialise up to six next-generation …
Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy
April 17, 2024Research and Development Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …
Novartis shares new data about Fabhalta for IgAN treatment
April 16, 2024Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …
GSK’s meningococcal vaccine candidate accepted for FDA review
April 16, 2024Medical Communications FDA, GSK, Immunology, meningococcal
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
April 15, 2024Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …
FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
April 15, 2024Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …
Lipocine announces results from phase 2 trial for obesity drug
April 12, 2024Research and Development Lipocine, Obesity, clinical trial, weight loss
Lipocine Inc has announced results from its phase 2 clinical trial (NCT04134091), which includes results for LPCN 2401, the company’s …
Latest content
FibroFind appoints Lee Borthwick as CEO
